title: Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz.
authors.forename: C
authors.initials: C
authors.lastname: Piketty
authors.forename: E
authors.initials: E
authors.lastname: Race
authors.forename: P
authors.initials: P
authors.lastname: Castiel
authors.forename: L
authors.initials: L
authors.lastname: Belec
authors.forename: G
authors.initials: G
authors.lastname: Peytavin
authors.forename: A
authors.initials: A
authors.lastname: Si-Mohamed
authors.forename: G
authors.initials: G
authors.lastname: Gonzalez-Canali
authors.forename: L
authors.initials: L
authors.lastname: Weiss
authors.forename: F
authors.initials: F
authors.lastname: Clavel
authors.forename: M D
authors.initials: MD
authors.lastname: Kazatchkine
mesh_terms: D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D004352:Drug Resistance, Microbial / Q000235:genetics*; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D010078:Oxazines / Q000627:therapeutic use; D010641:Phenotype; D019438:Ritonavir / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; C098320:efavirenz; D019258:Saquinavir; D019438:Ritonavir